头孢比罗酯钠(Ceftobiprole Medocaril Sodium) - 药物靶点：PBPs_在研适应症：社区获得性肺炎，医院获得性肺炎，新生儿败血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ceftobiprole medocaril free acid、ceftobiprole、ceftobiprole medocaril

+ [12]

靶点

PBPs

作用方式

抑制剂

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)

治疗领域

感染呼吸系统疾病遗传病与畸形+ [1]

在研适应症

社区获得性肺炎医院获得性肺炎新生儿败血症

非在研适应症

细菌感染社区获得性细菌性肺炎发热+ [14]

原研机构

Basilea Pharmaceutica AG

在研机构

Basilea Pharmaceutica AGBasilea Pharmaceuticals Deutschland GmbH

Avir Pharma, Inc.初创企业

非在研机构

Janssen Pharmaceutical Unlimited Co.Johnson & Johnson Pharmaceutical Research & Development LLCBasilea Pharmaceutica International Ltd.

最高研发阶段批准上市

首次获批日期

加拿大 (2018-03-20),

社区获得性肺炎医院获得性肺炎

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、合格传染病产品 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C26H26N8NaO11S2

InChIKeyBYUIXTXYXHAECA-LCJFHXTKSA-N

CAS号252188-71-9

查看全部结构式(2)

关联

36

项与头孢比罗酯钠相关的临床试验

NCT06808646

/ Completed临床1期

A Phase 1, Single-center, Open-label, Non-randomized, Fixed-sequence, Drug-drug Interaction Study to Assess the Effect of Repeated Doses of Intravenous Ceftobiprole on the Pharmacokinetics of Oral Pitavastatin (OATP1B Substrate) and on Plasma Levels of Coproporphyrin I (OATP1B Biomarker) in Healthy Subjects

The goal of this clinical study is to determine the effect of the test drug ceftobiprole (a drug approved for the treatment of bacterial infections) on the elimination of pitavastatin (a drug approved for the treatment of increased levels of cholesterol in blood) from the body. This interaction will be investigated by pharmacokinetic (PK) assessments.
The PK of pitavastatin will be assessed when administered alone and when administered together with ceftobiprole in a study design including two treatment periods.
The clinical study will also investigate the safety of ceftobiprole and how well ceftobiprole is tolerated by healthy subjects when it is administered in combination with pitavastatin. In addition, the effect of ceftobiprole on a specific marker, called coproporphyrin I, will be assessed in the blood.
The duration of the study will be a maximum of 38 days.

开始日期2025-01-17

申办/合作机构

Basilea Pharmaceutica AG

[+1]

ChiCTR2500096047

/ Recruiting早期临床1期IIT

Pharmacokinetic Characteristics and Blood-Brain Barrier Penetration of Ceftobiprole in Patients with Proposed or Confirmed Central Nervous System Infection

开始日期2024-10-28

申办/合作机构-

NCT05856227

/ Completed临床3期

A Multicenter, Open-label, Single-arm, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Ceftobiprole Medocaril in Term and Pre-term Neonates and Infants up to 3 Months of Age With Late-onset Sepsis

This study will evaluate the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.

开始日期2023-08-06

申办/合作机构

Basilea Pharmaceutica AG

100 项与头孢比罗酯钠相关的临床结果

登录后查看更多信息

100 项与头孢比罗酯钠相关的转化医学

登录后查看更多信息

100 项与头孢比罗酯钠相关的专利（医药）

登录后查看更多信息

448

项与头孢比罗酯钠相关的文献（医药）

2025-04-01·International Journal of Antimicrobial Agents

Safety of ceftobiprole in patients with impaired renal, hepatic or immune function: A multinational retrospective hospital chart review (RETRACE study)

Article

作者: Francisci, Daniela ; de Novales, Francisco Javier Membrillo ; Fernández-Hidalgo, Nuria ; Jemmely, Noëlle ; Falcone, Marco ; Estébanez, Miriam ; Durante-Mangoni, Emanuele ; Cedar, Eve ; Quevedo, Juan ; Gentile, Ivan ; Soriano, Alex

Ceftobiprole, an advanced-generation cephalosporin with broad bactericidal activity, is approved for community-acquired and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). We aimed to evaluate, in a real-world setting, the safety profile of ceftobiprole in patients with risk conditions (severe renal impairment, hepatic impairment, and immunocompromised status), groups excluded from clinical trials. In this retrospective study (NCT04170309), 396 consecutive charts of patients treated with ceftobiprole during 2016-2022 in 15 centers in France, Italy, and Spain were analyzed: 62 had severe renal impairment, 51 had hepatic impairment, 120 were immunocompromised, and 203 had no predefined risk condition (controls). Ceftobiprole was used for off-label indications in 110/396 (27.8%) patients; 46/396 (11.6%) patients received a higher-than-recommended dose. Treatment-emergent adverse events (TEAEs) considered as ceftobiprole-related occurred in 44 patients, more frequently in the risk groups compared to controls (severe renal impairment: 8/62 [12.9%]; hepatic impairment: 7/51 [13.7%]; immunocompromised: 19/120 [15.8%]; controls: 15/203, [7.4%]); in 7/44 patients, these events were serious. Compared to controls, liver-related AEs occurred more frequently in the impaired hepatic function (17/51 [33.3%] vs 22/203 [10.8%], odds ratio [OR:]: 4.11; 95% confidence interval [CI]: 1.98-8.55) and immunocompromised (30/120 [25.0%] vs 22/203 [10.8%], OR: 2.74; 95%CI: 1.50-5.02) groups. Hyponatremia was also more frequent in immunocompromised patients than controls (14/120 [11.7%] vs 9/203 [4.4%], OR: 2.85; 95%CI: 1.19-6.80). Underlying disease, concomitant medications and the poor health status of the patients likely affected these imbalances. Overall, no new safety concerns related to ceftobiprole use in real-world patients with severe renal impairment, hepatic impairment or immunocompromised status were identified.

2025-02-13·Antimicrobial Agents and Chemotherapy

Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022

Article

作者: Castanheira, Mariana ; Sader, Helio S. ; Smart, Jennifer I. ; Mendes, Rodrigo E.

ABSTRACT Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with Staphylococcus aureus bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant S. aureus (MRSA) and multidrug-resistant (MDR) S. aureus clinical isolates. A total of 19,764 S . aureus isolates were collected from patients with various infection types at 37 US medical centers from 2016 to 2022. Susceptibility testing was performed by broth microdilution according to Clinical and Laboratory Standard Institutes (CLSI) standards. Isolates were categorized as MDR if they were nonsusceptible by CLSI criteria to ≥3 antimicrobials. Ceftobiprole was highly active against MRSA ( n = 8,184; MIC 50/90 , 1/2 mg/L; 99.3% susceptible [S]) and MDR ( n = 2,789; MIC 50/90 , 1/2 mg/L; 98.1%S) isolates and retained activity against 87.3% of ceftaroline-nonsusceptible isolates ( n = 433; MIC 50/90 , 2/4 mg/L). Ceftobiprole demonstrated greater susceptibility rates than ceftaroline against all resistant subsets. Ceftobiprole was highly active against isolates nonsusceptible to clindamycin (98.0%S), daptomycin (100.0%S), doxycycline (98.2%S), erythromycin (99.5%S), gentamicin (98.1%S), levofloxacin (99.1%S), tetracycline (99.1%S), tigecycline (100.0%S), and trimethoprim-sulfamethoxazole (99.4%S) and isolates with decreased susceptibility to vancomycin (98.3%S).

2025-02-01·The Nurse Practitioner

Recent drug approvals, winter 2025 edition

Article

作者: Drake, Evan S. ; Anderson, James Layton ; Marino, Adriane B. ; Theroux, Jenna D. ; Self, Destiny S.

ABSTRACTIn the first half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article, the winter 2025 edition of the journal's biannual Drug Update, highlights the following new medications: sotatercept-csrk (Winrevair), aprocitentan (Tryvio), resmetirom (Rezdiffra), berdazimer (Zelsuvmi), ceftobiprole medocaril sodium (Zevtera), sofpironium (Sofdra), and ensifentrine (Ohtuvayre).

126

项与头孢比罗酯钠相关的新闻（医药）

2025-03-14

·GlobeNewswire-Health Care

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment. David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer, resulting in this first sales milestone for the Asia Pacific and China region this year, which significantly surpasses previous sales milestones for the region. This underscores the continued progress in making Cresemba available to increasing numbers of patients suffering from life-threatening invasive mold infections in this region.” The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region. Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD 533 million, a 20 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1 About Cresemba® (isavuconazole) Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@basilea.cominvestor_relations@basilea.com This press release can be downloaded from www.basilea.com. References IQVIA Analytics Link, September 2024. In-market sales reported as moving annual total (MAT) in US dollar.European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: March 13, 2025]Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: March 13, 2025]Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: March 13, 2025]The registration status and approved indications may vary from country to country. Attachment Press release (PDF)

引进/卖出上市批准

2025-03-13

·汇聚南药

5年新高！这一OTC龙头2024营收276亿元

昨日（3月12日），华润三九正式发布2024年年度报告，交出了一份营利双增的成绩单。财报显示，2024年华润三九营业收入为276.17亿元，同比增长11.63%；归属于上市公司股东的净利润为33.69亿元，同比增长18.05%；归属于上市公司股东的扣非净利润为31.18亿元，同比增长15.01%。图源：华润三九2024年年报同时，从近5年数据走势来看，华润三九业绩逐年增长，2024年是华润三九近5年来营收净利最高的一年。图源：富途分季度来看，第四季度营收最多，为78.76亿元；归母净利则是一年中最少，呈4.08亿元。这一反差或与年末并购天士力的资本开支及季节性营销投入有关。图源：华润三九2024年年报 01. 双轮驱动， “CHC+处方药”贡献66.95%营收据其官网介绍，华润三九是大型国有控股医药上市公司，主要从事医药产品的研发、生产、销售及相关健康服务。其前身是1985年成立的深圳南方制药厂，1999年，由三九企业集团、深圳三九药业股份有限公司等5家公司发起设立股份制公司。 2000年3月9日，华润三九在深圳证券交易所挂牌上市；2008年，正式进入华润集团；2010年，其名称由“三九医药股份有限公司”变更为“华润三九医药股份有限公司”。公开资料显示，华润三九主营核心业务定位于CHC健康消费品和处方药领域。其中，CHC健康消费品业务覆盖了感冒、皮肤、胃肠、止咳、骨科、儿科、膳食营养补充剂等近10个品类，其核心产品占据了较高的市场份额。处方药业务覆盖心脑血管、抗肿瘤、消化系统、骨科、儿科、抗感染等治疗领域，拥有血塞通三七系列产品、参附注射液、示踪用盐酸米托蒽醌注射液、华蟾素片剂及注射剂、益血生胶囊、瘀血痹、注射用头孢比罗酯钠等药品。年报透露，2024年，华润三九CHC业务营收124.82亿元，同比增长14.13%，占比总营收45.20%；处方药业务营收60.06亿元，同比增长15.04%，占比总营收21.75%。图源：华润三九2024年年报分地区来看，国内西部地区营收占比最重，且增长势头最猛；海外营收占比总营收虽然仅有1.07%，但同比增长27.60%。图源：华润三九2024年年报由上可见，中药OTC龙头华润三九不仅在CHC健康消费品和处方药两大核心业务板块取得了显著成就，也海外市场迈出了积极的步伐。2024年的财务数据不仅是对其市场战略和产品布局有效性的有力证明，也为未来的发展奠定了坚实的基础。 02. 并购扩张，不断“添将”多元布局在复杂多变的医药市场中，是什么因素驱动华润三九实现稳健的业绩增长？深入分析其背后的原因，不难发现，这既得益于华润三九对产品研发创新的持续投入，也与其在品牌建设、渠道拓展、数字化转型等方面的努力密切相关。 1.研发投入持续增长年报显示，华润三九的研发费用由2020年的5.81亿元提升至2024年的9.53亿元，增幅达63.97%。2024年华润三九在研项目共计131项，主要围绕抗肿瘤、骨科、皮肤、呼吸、抗感染等治疗领域。以临床价值为导向，聚焦核心领域，布局产品研发。图源：华润三九2024年年报 2. 并购整合多家药企近年来，随着国家对中医药发展的大力支持和监管力度的加大，行业整合已经成为大势所趋。华润三九也在积极通过并购加速中药业务的整合与发展。 2023年1月，昆药集团并入华润三九，昆药集团拥有完整的三七产业链，其血塞通系列产品在心脑血管领域具有显著的市场竞争力。并购后，华润三九逐步剥离了昆药集团的医药流通业务，并减少了非核心业务的股权，使其聚焦健康老龄化赛道。 2024年11月，昆药集团完成对圣火药业的并购。此次并购是为了解决昆药集团与华润三九旗下圣火药业在血塞通软胶囊产品上的同业竞争问题。并购后，昆药集团将统一血塞通市场，减少竞争，并作为唯一供货方掌控定价权。同时，整合后的团队、销售网络、供应链、品牌将更具竞争力和战斗力。同年8月，华润三九宣布以62亿元收购天士力28%股权。据其表示，双方合作将助力华润三九快速提升创新药研发能力、加快补充创新中药管线，促进公司处方药业务达成业务发展目标。 3. 加强渠道建设及管理本次年报中，华润三九表示，CHC业务依托于三九商道的客户体系，与全国经销商和连锁终端广泛深入合作，覆盖全国超60万家药店。处方药业务覆盖数千家等级医院、数万家基层医疗机构，并拥抱互联网医疗的浪潮。在线上领域，其与京东大药房、阿里健康大药房、平安好医生等建立了战略伙伴关系，拓展业务边界。此外，其深化与各大线上零售平台的合作，借助大数据分析目标客户群体需求，优化产品设计。积极布局新兴业务模式，推动线上线下全渠道融合。加强数字化能力打造，加大对大数据、AI创新技术探索，助推产业智能化转型。由此来看，业绩增长并非偶然。但在持续增长的背后，也隐藏着一些不容忽视的挑战与隐忧。 03. 风险并存，增长之下仍有“隐忧” 最首要的还是集采的影响。去年9月，安徽省发布2024年度中成药集采征求意见稿，计划对35个中成药品种进行集采，这也是OTC药品首次被纳入集采目录。华润三九股价一度下滑，累计跌超18%，市值蒸发超百亿。本次年报亦有提及，集采药品的覆盖面进一步扩大。集采政策的实施可能对公司营业收入及盈利能力造成一定影响。再者，医保飞检覆盖范围扩大及医药领域反腐整治常态化，短期内可能延缓处方药进院节奏。华润三九在年报中表示，医药行业整治短期内对医药企业的学术推广活动和产品进院工作产生一定影响。此外，原材料价格波动。2024年中药材大盘指数走势呈现出先扬后抑的特点，年初至年中，受产量下降、库存紧张或需求增加、资金炒作等因素影响，多个品种打破历史最高价，下半年市场在产能恢复、需求疲软的共同影响下出现了旺季不旺的反差，呈现一路下滑的走势，不少高价品种价格回落明显。图源：华润三九2024年年报除上所述，华润三九的高层管理人员变动较为频繁，辞职原因大部分为工作变动。公司副总裁徐永前、董事梁征等多名董监高人员辞职，可能对公司的战略稳定性和业务连续性造成一定影响，同时也可能引发市场对其未来发展的不确定性担忧。并购整合方面虽取得了一定成果，但整合过程中也面临着多项挑战。如何充分发挥并购企业的协同效应，提升整体竞争力，是华润三九需要面对的重要问题。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~ 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：药闻天下往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

财报核酸药物

2025-02-18

·FierceBiotech

Basilea opts not to take MRSA antibiotic into clinic due to \'stringent risk-return criteria\'

“This decision demonstrates that we are focused on stringent risk-return criteria when making portfolio decisions,” Basilea Pharmaceutica said.\n Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development.Basilea secured the license option for the endolysin antibiotic, called tonabacase, from Korea’s iNtRON Biotechnology in 2023. Basilea had been conducting a preclinical evaluation of the asset throughout 2024 ahead of a decision on whether to secure the exclusive rights to take tonabacase into human trials.When it signed the agreement with iNtRON, Basilea pointed to preclinical evidence of tonabacase’s activity against methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA) as well as coagulase-negative staphylococci.“There continues to be a high medical need for new treatment options for patients with persistent infections caused by Gram-positive bacteria and tonabacase is an exciting and innovative asset for us to evaluate over the coming months,” Basilea Chief Medical Officer Marc Engelhardt, M.D., said back in 2023. “If the outcome of our evaluation is positive and we enter into a full license agreement, we may be able to start directly a phase 2 clinical study in 2025.” That trial is now off the menu, as Basilea has completed its own preclinical profiling of the medicine and “taken the decision not to pursue further development,” the Swiss company said in its full-year earnings report.“This decision demonstrates that we are focused on stringent risk-return criteria when making portfolio decisions,” the company added.Basilea currently markets Cresemba for invasive fungal infections and Zevtera for bacterial infections. The low return on investment means many of the biggest biopharmas have given up working on new antifungals or antibiotics in recent years—although GSK in particular has continued to sign deals and post encouraging clinical results against infections like gonorrhea.Meanwhile, Basilea has swum against the tide, pivoting away from cancer toward anti-infectives last year. The company’s clinical pipeline is headed up by fosmanogepix, an antifungal licensed from Amplyx Pharmaceuticals that Basilea is planning to enter into its second phase 3 study against mold infections.Basilea’s work developing new antifungals received a significant boost last September from the U.S. Department of Health and Human Services, which signed off on up to $268 million of funding to the biopharma over more than a decade.

$Basilea opts not to take MRSA antibiotic into clinic due to \'stringent risk-return criteria\'$

引进/卖出临床3期

100 项与头孢比罗酯钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	头孢比罗酯钠	J01DI01	DB14733

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
社区获得性肺炎	加拿大	Avir Pharma, Inc.初创企业	2018-03-20
医院获得性肺炎	加拿大	Avir Pharma, Inc.初创企业	2018-03-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
传染性皮肤病	临床前	欧盟	Janssen Pharmaceutical Unlimited Co.	-
软组织感染	临床前	欧盟	Janssen Pharmaceutical Unlimited Co.	-
皮肤和皮肤结构感染	药物发现	美国	Basilea Pharmaceutica International Ltd.	2024-04-03
金黄色葡萄球菌菌血症	药物发现	美国	Basilea Pharmaceutica International Ltd.	2024-04-03
医疗保健相关性肺炎	药物发现	-	Basilea Pharmaceutica AG	2005-04-01
葡萄球菌皮肤感染	药物发现	-	Basilea Pharmaceutica AG	2004-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03137173 (FDA_CDER) 人工标引	临床3期	皮肤和皮肤结构感染	679	ZEVTERA 667 mg	(鹹襯製鹹構衊餘鏇築餘) = 選觸積壓襯糧窪鑰選鑰鹹蓋遞窪鑰鹽淵鏇簾齋 (鏇繭簾廠遞鹽鹹襯廠顧 ) 更多	积极	2024-04-03
				Vancomycin plus aztreonam	(鹹襯製鹹構衊餘鏇築餘) = 鹹鑰築鬱獵壓鹹鹹夢憲鹹蓋遞窪鑰鹽淵鏇簾齋 (鏇繭簾廠遞鹽鹹襯廠顧 ) 更多
NCT03138733 (FDA_CDER) 人工标引	临床3期	金黄色葡萄球菌菌血症	387	ZEVTERA	(構夢衊糧餘鹹蓋觸顧憲) = 蓋窪遞鑰觸壓簾蓋窪製憲製觸繭獵餘襯夢窪廠 (醖鬱鑰襯築淵範衊築衊 ) 更多	积极	2024-04-03
				Daptomycin	(構夢衊糧餘鹹蓋觸顧憲) = 鹽醖範鏇鹹衊繭製網獵憲製觸繭獵餘襯夢窪廠 (醖鬱鑰襯築淵範衊築衊 ) 更多
NCT00326287 \| NCT03439124 (FDA_CDER) 人工标引	临床3期	社区获得性细菌性肺炎	-	Ceftobiprole medocaril (Adult Patients)	(廠鏇鹹鬱獵選鹹蓋繭範) = 鏇醖觸製鏇構積廠蓋壓鑰夢觸壓廠壓遞繭齋網 (鹹窪壓艱齋鏇襯廠憲廠 ) 更多	积极	2024-04-03
				Ceftriaxone with or without Linezolid (Adult Patients)	(廠鏇鹹鬱獵選鹹蓋繭範) = 窪獵築憲壓顧築網網壓鑰夢觸壓廠壓遞繭齋網 (鹹窪壓艱齋鏇襯廠憲廠 ) 更多
NCT03138733 (ERADICATE, Corporate Publications) 人工标引	临床3期	金黄色葡萄球菌菌血症	390	Ceftobiprole Medocaril Sodium	廠網鹽夢鹹糧願範襯積(鬱襯淵鹹餘鏇製鹽築蓋) = 構憲顧積鬱鹹觸願蓋餘選製鏇鏇獵繭鬱選鬱鏇 (鹽廠夢襯憲築繭積築襯 ) 更多	非劣	2022-10-24
				Aztreonam+Daptomycin	廠網鹽夢鹹糧願範襯積(鬱襯淵鹹餘鏇製鹽築蓋) = 繭齋廠齋糧鬱網憲遞憲選製鏇鏇獵繭鬱選鬱鏇 (鹽廠夢襯憲築繭積築襯 ) 更多
NCT02527681 \| NCT03439124 (Pubmed \| Pediatr Infect Dis J)	N/A	-	-	Ceftobiprole (Neonates and infants up to 3 months of age)	(廠糧膚夢簾鏇選範鹽積) = 鏇構築憲顧淵鑰衊簾繭願鏇鏇觸構鬱繭憲鬱糧 (製製遞鹹醖艱夢遞繭膚 ) 更多	-	2021-11-01
				Ceftobiprole (Patients 3 months to 17 years of age)	(廠糧膚夢簾鏇選範鹽積) = 淵構網憲鹹繭鹹鹹製壓願鏇鏇觸構鬱繭憲鬱糧 (製製遞鹹醖艱夢遞繭膚 ) 更多
NCT03137173 (TARGET, Pubmed \| Clin Infect Dis) 人工标引	临床3期	皮肤和皮肤结构感染	679	Ceftobiprole Medocaril Sodium	(艱繭簾襯顧築繭獵鹽膚) = 簾願醖製簾構艱顧積廠廠窪夢觸築鏇鹽築選膚 (製鬱範網蓋糧鑰範衊鹽 ) 更多	非劣	2021-10-05
				Vancomycin Hydrochloride+Aztreonam	(艱繭簾襯顧築繭獵鹽膚) = 顧憲膚鑰選醖膚鏇蓋鬱廠窪夢觸築鏇鹽築選膚 (製鬱範網蓋糧鑰範衊鹽 ) 更多
NCT03439124 (Pubmed \| Pediatr Infect Dis J)	临床3期	儿童肺炎	138	Ceftobiprole	(襯構糧築製遞鑰淵襯壓) = 憲糧襯膚餘夢醖憲艱齋獵艱壓選鹽膚選夢艱壓 (醖積顧衊壓夢繭糧構膚 ) 更多	积极	2021-01-21
				Standard-of-care IV cephalosporin treatments (ceftazidime or ceftriaxone)	(襯構糧築製遞鑰淵襯壓) = 鹹網衊衊遞鹽顧簾鏇簾獵艱壓選鹽膚選夢艱壓 (醖積顧衊壓夢繭糧構膚 ) 更多
NCT02527681 (CTgov)	临床1期	细菌感染	15	Ceftobiprole (Ceftobiprole PK Population)	(膚網壓獵壓網遞膚壓廠) = 選糧鏇廠鑰衊淵夢積襯鏇衊夢壓簾構鬱淵窪膚 (範餘淵鹹繭網選壓繭製, 膚築網餘壓顧鑰淵壓蓋 ~ 糧簾簾淵觸顧網鹽壓鹽) 更多	-	2021-01-06
				Ceftobiprole (Ceftobiprole ITT/Safety Population)	餘鑰範壓簾餘蓋積範襯(範鏇醖蓋鏇齋鏇鬱繭襯) = 窪範鬱淵築鑰蓋衊蓋遞鹽積廠餘廠鬱製鏇艱鏇 (繭構遞憲壓網選願餘構, 製鹽選醖齋範繭淵夢鬱 ~ 網範壓襯範衊築糧鹽構) 更多
NCT03439124 (Trial 5, CTgov)	临床3期	社区获得性肺炎 \| 医院获得性肺炎	138	ceftobiprole medocaril (Ceftobiprole Medocaril)	鹹築製壓範鑰廠糧襯醖(製觸壓蓋艱齋積淵夢鹹) = 築範鹽衊築遞夢獵壓鹹憲顧構蓋醖鬱廠遞壓醖 (網壓艱廠顧築鏇簾鏇艱, 蓋製網襯製簾壓構選憲 ~ 醖齋廠廠餘範選築醖襯) 更多	-	2020-09-11
				IV standard-of-care cephalosporin (IV Standard-of-care Cephalosporin)	鹹築製壓範鑰廠糧襯醖(製觸壓蓋艱齋積淵夢鹹) = 醖築淵築壓艱淵網構積憲顧構蓋醖鬱廠遞壓醖 (網壓艱廠顧築鏇簾鏇艱, 範鹹鏇膚蓋糧膚醖糧憲 ~ 製顧餘淵醖膚憲鹽鹹艱) 更多
NCT03137173 (TARGET \| Trial 2, CTgov)	临床3期	皮肤和皮肤结构感染	679	ceftobiprole medocaril (Ceftobiprole Medocaril)	(艱膚襯鏇壓範製築顧觸) = 齋鏇膚餘衊淵壓壓製遞遞範獵鹹鑰壓膚壓醖窪 (繭簾顧獵憲選襯蓋蓋鑰, 襯鏇艱夢鹹淵顧鬱憲壓 ~ 膚艱齋齋膚糧膚壓艱衊) 更多	-	2020-05-18
				aztreonam+vancomycin (Vancomycin+Aztreonam)	(艱膚襯鏇壓範製築顧觸) = 膚蓋餘獵鬱襯獵鏇願憲遞範獵鹹鑰壓膚壓醖窪 (繭簾顧獵憲選襯蓋蓋鑰, 襯廠糧鹽衊憲鑰網構壓 ~ 願蓋觸艱獵艱製範選醖) 更多